A phase III trial of Arzerra as a maintenance therapy for chronic lymphocytic leukemia met its primary endpoint of extending progression-free survival at an interim analysis.
A German company that makes devices now under FDA scrutiny for their potential to spread sarcoma threatened legal action against the U.S. surgeon whose wife's cancer cells were disseminated during routine surgery to remove fibroids.
Emmanuel Farber, a pathologist who made contributions to the understanding of chemical carcinogenesis, died Sunday, Aug. 3.
Ethicon, the Johnson & Johnson subsidiary that manufactures nearly three-quarters of laparoscopic power morcellators on the market, has requested a withdrawal of the controversial devices.
FDA approved Zydelig (idelalisib) tablets for the treatment of three B-cell blood cancers.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A phase II study by the University of Florida Proton Therapy Institute shows that the use of proton therapy following chemotherapy in 15 patients with Hodgkin lymphoma has a success rate similar to the conventional treatments with a reduction of radiation outside of the target area, potentially reducing the risk of late effects caused by radiation.
An NCI study found that a negative HPV screening test result is a better predictor of low cervical cancer risk than a negative Pap test.
A phase II study of older patients with untreated acute myeloid leukemia showed that treatment with volasertib and low-dose cytarabine more than doubled the objective response rate compared to cytarabine chemotherapy alone.
